Nostopharma announced it raised $250,000 in an initial filing from an offering of $250,000

Company

Location

About

Nostopharma is a provider of pathologic bone growth treatment aimed at preventing rare bone diseases, reducing complications from traumatic injuries, and lowering societal costs associated with rehabilitation for surgery patients. The company offers a nanoparticle drug delivery system for treating soft tissue trauma complications and helps patients form new bone following surgeries, burns, injuries, and other traumas, enabling healthcare providers to improve clinical outcomes for patients with post-traumatic injuries.